The addition of bevacizumab , as compared with neoadjuvant therapy alone , was associated with a higher incidence of grade 3 or 4 toxic effects ( febrile neutropenia , mucositis , the hand-foot syndrome , infection , and hypertension ) but with a similar incidence of surgical complications .
